New option for cisplatin-ineligible urothelial cancer

Affiliations

Comment

Robert Dreicer. Lancet Oncol. 2017 Nov.

. 2017 Nov;18(11):1428-1430.

doi: 10.1016/S1470-2045(17)30602-2. Epub 2017 Sep 26.

¹ University of Virginia, Charlottesville, VA 22908, USA. Electronic address: dreicer@virginia.edu.

No abstract available

Comment on

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. Balar AV, et al. Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26. Lancet Oncol. 2017. PMID: 28967485 Clinical Trial.